Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

In Memoriam: Lawrence Crane Wood (1935-2026).

Thyroid : official journal of the American Thyroid Association·2026
Same author

Rethinking paracorporeal lung assist device support in the modern era: Why so different than ECMO?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

In Memoriam: Lawrence Crane Wood (1935-2026).

Thyroid : official journal of the American Thyroid Association·2026
Same author

Kidney and blood pressure sequelae after pediatric extracorporeal membrane oxygenation: a secondary analysis of the Kidney Injury During Membrane Oxygenation pediatric ECMO cohort.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Endocrine Effects of Arginine-Vasopressin After Pediatric Cardiac Surgery.

Pediatric cardiology·2025
Same author

Increased utilisation of analgesia and sedation in patients following bidirectional Glenn: evidence for the "Glenn Headache"?

Cardiology in the young·2025
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: May 25, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

サブクリニック性甲状腺疾患

David S Cooper1, Bernadette Biondi

  • 1Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. dscooper@jhmi.edu

Lancet (London, England)
|January 26, 2012
PubMed
まとめ
この要約は機械生成です。

軽度の甲状腺機能過剰症や甲状腺機能低下症を含むサブ臨床的甲状腺疾患は一般的であるが,その臨床的影響は不明である. これらの甲状腺機能障害の診断と治療を導くためにさらなる研究が必要である.

関連する実験動画

Last Updated: May 25, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

科学分野:

  • エンドクリノロジー エンドクリノロジー
  • 内科内科は,内科の内科である.
  • 甲状腺学 甲状腺学について

背景:

  • 軽度の甲状腺機能不全を特徴とするサブ臨床的甲状腺疾患は頻繁に発生します.
  • サブクリニック性甲状腺機能過剰症およびサブクリニック性甲状腺機能低下症の臨床的意義と管理は,現在進行中の議論の対象となっています.

研究 の 目的:

  • 準臨床的甲状腺疾患の定義,疫学,診断,進行をレビューする.
  • サブクリニックの甲状腺機能不全の潜在的な健康結果と管理戦略について議論する.
  • この分野における大規模なランダム化試験の必要性を強調する.

主な方法:

  • 副臨床的な甲状腺疾患に関する現在の証拠の文献レビューと合成.
  • 明らかに甲状腺疾患に進行するための診断基準とリスクの階層化の議論.
  • 甲状腺を刺激するホルモンのレベルと併発性疾患に基づいた治療勧告の分析.

主要な成果:

  • サブクリニカル型甲状腺疾患は,甲状腺の軽度の過剰活動または不活性を示し,臨床的影響は不明である.
  • 副臨床的な甲状腺機能不全の治療の決定は,甲状腺刺激ホルモンの偏差の重症度と患者の併発性疾患に依存します.
  • 現在の証拠は,管理を明確に導くには不十分であり,さらなる研究が必要である.

結論:

  • サブクリニックの甲状腺疾患は一般的ですが,その臨床的意義についてはさらなる解明が必要です.
  • 管理戦略は,個々の患者の要因と甲状腺機能障害の程度を考慮する必要があります.
  • 大規模なランダム化対照試験は,サブ臨床的な甲状腺疾患の最適なケアガイドラインを確立するために不可欠です.